| Literature DB >> 33012328 |
Abstract
Allergic diseases represent some of the most chronic and costly chronic conditions. Medical management may require long-term pharmacotherapy, which is often associated with poor adherence. Although medications provide symptomatic control, they do not modify the allergic disease. Patients may prefer disease-modifying treatments that provide lasting benefits after discontinuation. To date, allergy immunotherapy is the only proved disease modification therapy associated with lasting benefits after discontinuation. However, allergy immunotherapy safety and efficacy has only been established in allergic rhinitis, mild to moderate asthma, and some patients with atopic dermatitis.Entities:
Keywords: Allergy immunotherapy; Atopic dermatitis; Biologics; Mepolizumab; Omalizumab; Rhinosinusitis with nasal polyps; Subcutaneous immunotherapy; Sublingual immunotherapy
Year: 2020 PMID: 33012328 DOI: 10.1016/j.iac.2020.06.008
Source DB: PubMed Journal: Immunol Allergy Clin North Am ISSN: 0889-8561 Impact factor: 3.479